Section Arrow
UNCY.NASDAQ
- Unicycive Therapeutics
(Financial Status)
Quotes are at least 15-min delayed:2024/10/31 18:49 EDT
Last
 0.5291
+0.0191 (+3.75%)
Day High 
0.549 
Prev. Close
0.51 
1-M High
0.529 
Volume 
1.63M 
Bid
0.5251
Ask
0.5399
Day Low
0.5011 
Open
0.52 
1-M Low
0.34 
Market Cap 
48.12M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.45 
20-SMA 0.41 
50-SMA 0.39 
52-W High 1.818 
52-W Low 0.202 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.36/-0.33
Enterprise Value
48.59M
Balance Sheet
Book Value Per Share
-0.16
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
675.00K
Operating Revenue Per Share
0.02
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABElevai Labs0.059-0.0339-36.49%-- 
AVTEAerovate Therapeutics2.46+0.27+12.33%-- 
ENSCEnsysce Biosciences0.5754-0.0629-9.85%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.1445-0.0099-6.41%-- 
GLYCGlycoMimetics0.4069-0.0496-10.87%-- 
Quotes are at least 15-min delayed:2024/10/31 18:49 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.